Marinus Pharmaceuticals (NASDAQ:MRNS) Earns “Buy” Rating from HC Wainwright

Marinus Pharmaceuticals (NASDAQ:MRNS)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They currently have a $27.00 price target on the biopharmaceutical company’s stock.

Several other brokerages also recently issued reports on MRNS. StockNews.com downgraded shares of Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 6th. Robert W. Baird reiterated a “neutral” rating on shares of Marinus Pharmaceuticals in a research report on Tuesday. Royal Bank of Canada reissued a “sector perform” rating and set a $3.00 target price (down previously from $24.00) on shares of Marinus Pharmaceuticals in a research report on Monday. Cantor Fitzgerald reiterated an “overweight” rating and set a $28.00 price objective on shares of Marinus Pharmaceuticals in a research note on Wednesday, April 10th. Finally, Oppenheimer reaffirmed a “market perform” rating and set a $9.00 price target on shares of Marinus Pharmaceuticals in a research report on Thursday, March 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Marinus Pharmaceuticals has an average rating of “Hold” and an average price target of $18.21.

Marinus Pharmaceuticals Trading Down 0.8 %

Shares of NASDAQ:MRNS traded down $0.01 during trading on Tuesday, hitting $1.29. The company had a trading volume of 10,333,766 shares, compared to its average volume of 1,068,217. The stock has a market cap of $70.86 million, a price-to-earnings ratio of -0.49 and a beta of 0.91. The company has a debt-to-equity ratio of 5.68, a current ratio of 4.07 and a quick ratio of 4.01. The company has a fifty day simple moving average of $9.06 and a two-hundred day simple moving average of $8.55. Marinus Pharmaceuticals has a one year low of $1.23 and a one year high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative return on equity of 269.75% and a negative net margin of 456.31%. The company had revenue of $7.19 million during the quarter, compared to the consensus estimate of $7.78 million. During the same quarter in the prior year, the business earned ($0.76) earnings per share. As a group, equities analysts forecast that Marinus Pharmaceuticals will post -2.43 earnings per share for the current year.

Hedge Funds Weigh In On Marinus Pharmaceuticals

A number of institutional investors have recently bought and sold shares of MRNS. Vanguard Group Inc. increased its holdings in Marinus Pharmaceuticals by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 2,577,475 shares of the biopharmaceutical company’s stock worth $20,749,000 after acquiring an additional 31,233 shares in the last quarter. Schonfeld Strategic Advisors LLC raised its holdings in shares of Marinus Pharmaceuticals by 69.5% during the third quarter. Schonfeld Strategic Advisors LLC now owns 253,412 shares of the biopharmaceutical company’s stock valued at $2,040,000 after acquiring an additional 103,935 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its position in shares of Marinus Pharmaceuticals by 6.3% in the third quarter. Adage Capital Partners GP L.L.C. now owns 2,904,476 shares of the biopharmaceutical company’s stock valued at $23,381,000 after acquiring an additional 173,226 shares in the last quarter. Jennison Associates LLC boosted its stake in shares of Marinus Pharmaceuticals by 58.4% in the third quarter. Jennison Associates LLC now owns 2,955,343 shares of the biopharmaceutical company’s stock worth $23,791,000 after acquiring an additional 1,089,913 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in Marinus Pharmaceuticals by 383.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,307 shares of the biopharmaceutical company’s stock valued at $69,000 after purchasing an additional 5,003 shares during the last quarter. 98.80% of the stock is owned by hedge funds and other institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.